Introduction
The examination of genetic attributes of neurocognition (ie, cognitive neurogenetics) to understand and uncover the underlying biological mechanisms of the pathogenesis as well as clinically viable biomarkers for early identification of HIV-associated neurocognitive disorders (HAND) has become an exciting aspect of NeuroAIDS research. 1 Genomic biomarkers for HAND could assist physicians in their determination of whether further neurological investigation would be valuable and/or assist in tailoring pharmacological interventions. In addition, genomic biomarkers have the potential to improve screening, diagnostic, staging and/or prognostic procedures. 2, 3 To date, the majority of genetic work related to neurocognitive performance, HAND, and other neurobehavioral disorders has been candidate-gene driven and concerned primarily with testing genotypic associations for neurocognitive performance among a small pool of candidate genes. 1, 4 To our knowledge, no study has attempted to examine gene expression and/or pathway associations with neurocognitive performance. This type of analysis may be advantageous in that it could identify novel candidate genes and/or biological pathways from which additional candidate genes could be extracted submit your manuscript | www.dovepress.com
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Bousman et al and further investigated for their significance. In this study, we sought to explore a blood-based genomic expression and pathway analysis approach to neurocognitive performance among a group of healthy adults rather than those with HAND to avoid confounds related to medication or disease status and to provide preliminary data for a novel method that could be used in future biomarker discovery efforts.
Methods subjects
Ten healthy volunteers were recruited from the University of California, San Diego Psychopharmacology Research Initiatives Center for Excellence participant network and clinically assessed using the Diagnostic Interview for Genetic Studies (DIGS) 5 as described elsewhere. 6 Participants were free of: (1) substance abuse or dependence in the past year; (2) neurologic problems (eg, stroke); (3) systemic medical illnesses (eg, diabetes, HIV); (4) history of head injury with documented loss of consciousness lasting longer than 10 minutes; (5) pregnancy; (6) physical disabilities; (7) use of prescribed medications; (8) current tobacco use; or (9) a personal or family history of a schizophrenia, bipolar disorder, major depressive disorder, or a cluster-A (schizotypal, schizoid, or paranoid) personality disorder, all of which may affect gene expression. All study procedures were approved by the Institutional Review Board at University of California, San Diego.
Neurocognitive assessment
Participants were administered the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus cognitive battery (MCCB). 7, 8 The MCCB contains 10 tests representing 7 domains, takes approximately 60 minutes to administer (for more details on the battery see references 7 and 8), and contains neurocognitive tests within the domains required for diagnosing HAND 9 ( Table 1) . The MCCB was administered by a trained Master's-level research assistant, on a single occasion, and in the order listed in Table 1 .
Blood collection and processing
Whole blood (10 mL) was collected in the morning after subjects fasted overnight but directly prior (, 30 minutes) to administration of the neurocognitive battery. Blood samples were immediately transferred to an RNase-free laboratory, where all subsequent procedures (ie, stabilization, isolation, storage) took place. 6 Prior to hybridization, two subjects were excluded for low RNA integrity (RIN , 6.0). 10 The remaining eight samples were then transcribed to cDNA and hybridized to GeneChip ® Human Exon 1.0 ST Arrays (Affymetrix, Inc., Santa Clara, CA, USA) per the "Whole Transcript (WT) Sense Target Labeling Assay" protocol (Affymetrix, 2006) using 1 µg of total RNA from each sample.
Microarray data analyses
The principal analyses of these data were designed to explore gene expression and pathway correlates among the 10 neurocognitive tests in the battery described above, as well as to potentially demonstrate the utility of a more robust biomarker discovery method for neurocognitive performance. To accomplish this, microarray data were imported into Partek Genomics Suite software (Partek Inc., St Louis, MO, USA) 
Pathway analysis
Following correlational analysis of individual gene transcripts, gene lists containing all nominally (P , 0.05) significantly correlated genes for each of the 10 neurocognitive tests were generated. These lists were then imported into Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems ® , Redwood City, CA, USA) to associate correlated genes with their representative canonical pathways. Canonical pathways that were most significant to the selected gene lists were identified by querying the IPA library of canonical pathways. The significance of the association between the datasets and the canonical pathways was measured in two ways: (1) using the Fischer's exact test, we calculated the probability that the association between the gene list and the canonical pathway was explained by chance alone; and (2) we calculated a ratio of the number of genes from the gene list that mapped to the pathway divided by the total number of molecules that exist in the canonical pathway. Pathways with a high ratio and a low P-value were interpreted as indicative of potentially good candidates for further exploration.
Results
Participant characteristics
Participant characteristics and raw neurocognitive test scores for each of the eight participants are shown in Table 2 . Participants ranged in age from 37-53 years (M = 45, sd = 7), were predominantly Caucasian (63%) and male (63%), and had completed between 12 and 17 years (M = 15, sd = 2) of education. Mean raw scores for each neurocognitive test among participants were in the normative range of those reported among healthy subjects recruited to determine norms for the MCCB. (5) 27 (4) 16 (3) 15 (2) 27 (5) 26 (4) 58 (14) 25 ( (Table 3 ). 63% (4116/6496) of these genes were correlated with a single neurocognitive test only. None of the genes was significantly correlated with more than three tests. Interestingly, the letter-number span, animal-naming, and MSCEIT tests showed the most unique gene expression correlates in that the unique proportion (ie, number of genes only significant for the test/total number of significant genes for the test) of correlated genes for these tests was 68%, 85%, and 100%, respectively (Table 3) . In contrast, the other tests showed less than 50% (range: 22%-47%) uniqueness and thus shared a greater majority of their gene correlates with other tests in the MCCB. It should be noted that due to the small sample size, the large number of comparisons made, and the consequent severity of the penalty for multiple testing, no individual gene correlate remained significant after correction (ie, 10% FDR). However, correlation coefficients (r) ranged from 0.98 to -0.98 and large effect sizes (r . ±0.49) 11 were observed for a majority of the nominally significant genes for most of the individual tests and domains (Table 3) .
canonical pathway correlates of neurocognitive performance
Examination of the top 10 canonical pathways populated by all the correlated genes for each of the 10 MCCB tests (Supplemental Table 1 ) showed that 80% of pathways were unique to one of the 10 tests. No pathways overlapped with all MCCB tests. Although, NF-kß signaling, N-Glycan degradation, one carbon pooling by folate, and phenylalanine metabolism canonical pathways were the most represented pathways among the MCCB, with each of these pathways mapping onto 3 or more of the 10 tests. Table 4 provides a comprehensive summary of gene and canonical pathway overlap among the tests of the MCCB.
Discussion
This study sought to explore the relationship between bloodbased gene expression and neurocognitive performance among healthy adults to avoid confounds related to medication or disease status and provide preliminary data for a novel method that could be used in future biomarker discovery efforts in HAND as well as other neurocognitive-related disorders. We found that nominally significant (P , 0.05) neurocognitive performance-associated genes mapped onto several canonical pathways, particularly those involved in cell signaling or metabolism. Among the top 10 pathways across the 10 tests (k = 100), 49% were signaling and 17% were metabolism pathways. It should be noted that these pathways have extensive interactions with a variety of biological processes such as cell growth, proliferation, and apoptosis, 12 so it is not surprising that these pathways are represented in associations with neurocognitive performance. In fact, several studies of HAND have investigated gene polymorphisms in signaling (eg, chemokine and dopamine receptors) and to lesser extent metabolism pathways (eg, dopamine metabolism). 13 when examined from a blood-based genomic perspective. This is particularly relevant to future biomarker discovery efforts in HAND in that the current diagnosis of HAND requires assessment of at least five areas of neurocognitive functioning known to be affected by HIV (eg, executive functioning, episodic memory, speed of information processing, motor skills, attention/working memory, language, and sensoriperception) but does not stipulate the use of any particular neurocognitive tests. 9 From a genomic perspective, HAND diagnosed using the current criteria may be very heterogeneous and result in difficulties with biomarker discovery and replication. Thus, if our results are replicated in a larger sample, this ultimately could advocate for restructuring of domains, examination of neurocognitive tests independent of domain membership, or adoption of a specific core group of neurocognitive tests for future genetic research related to biomarker discovery in HAND.
It must be acknowledged that these explanations are both speculative and post hoc. Moreover, there are several areas of overlap in cognitive component processes across tests that do not coincide with gene or pathway overlap. Further exploration is clearly needed, but the present results provide preliminary evidence that this approach might be useful in elucidating genetic biomarkers for cognitive processing and ultimately HAND. In so doing, this approach might also lead to novel ways to organize or select cognitive tests for HAND diagnosis. Indeed, it is worth noting that the cognitive tests used in the present study as well as many similar tests commonly employed were not designed for genetic studies, 14 and current ways of organizing cognitive measures may not map neatly onto gene expression or canonical pathways.
Several caveats should be considered when interpreting these results and addressed in future investigations. First, it remains unclear whether molecular signatures in blood accurately reflect those found in the brain. However, several investigators have reported that the circulating blood may act as a "sentinel tissue", 15 "neural probe", 16 or "surrogate" 17 for underlying pathophysiology in brain disorders. In fact, Liew and colleagues 15 reported an 80% overlap between blood and brain gene expression. Furthermore, blood-based approaches allow for better standardization of technical procedures and the ability to profile human subjects in a relatively non-invasive manner.
18,19 Second, we attempted to limit the influence of different subtypes of cells in blood by focusing on leukocytes. Within this cell category, several cell types (ie, neutrophils, eosinophils, basophils, lymphocytes, monocytes, and macrophages) with varying roles in the blood exist and may influence gene expression 
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Bousman et al profiles. 20 Future blood-based studies may find it advantageous to isolate specific lymphocyte subtypes in an effort to achieve greater sensitivity in detecting gene expression changes. Third, the sample size was small, which may have prohibited detection of effects that would have retained statistical significance in a larger sample, even after correcting for multiple testing. In fact, large expression effects (r . ±0.49) 11 were observed for a majority of genes for each of the MCCB tests suggesting many of these genes may have been significant in a larger sample and justify further investigation. Fourth, pathway-level analysis was done using one of the largest knowledge bases of biological networks (IPA, Redwood City, CA, USA), a considerable strength. However, IPA is manually curated and relies on previously published findings on mammalian biology. Thus, in some cases cellular component annotation can be missing or incomplete due to the lack of information in protein databases to which IPA is linked (eg, UniProt) and ultimately may underestimate extracellular entities (eg, metabolites, hormones). 21 Fifth, expression profiles were based on samples collected immediately (, 30 minutes) prior to cognitive testing. Thus, expression and pathway profiles observed in this study are not a result of cognitive performance tests but rather potential markers for performance ability. Future longitudinal research that examines expression profiles before and after neurocognitive testing could further elucidate the biological mechanisms underlying neurocognitive performance. Sixth, this study utilized the MATRICS consensus cognitive battery which was designed to evaluate cognitive-enhancing agents and other interventions to treat core cognitive deficits of schizophrenia and not necessarily for the identification of genomic markers for neurocognitive performance or HAND. Thus, it is possible that use of other neurocognitive tests and/or batteries will yield different results. Finally, in an effort to conserve power, potentially influential covariates (eg, age, gender, diet, and exercise) were not adjusted for in our analysis. Future studies with larger samples that have the power to include more covariates are warranted.
Despite these limitations, our work provides preliminary data for the application of genomic expression and pathway analysis to tests of neurocognitive performance. This approach may provide the potential for improving our ability to identify genomic markers of HAND as well as provide guidance to physicians and researchers in HIV medicine and other disciplines in their pursuit of viable genomic biomarkers for neurocognitive impairment.
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